drug adverse effects of oral glucosuric agent; SGLT-2 inhibitor; flozin

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21]

Adverse effects

* FDA decides no action necessary[4]

Notes

More general terms

References

  1. ↑ 1.0 1.1 FDA MedWatch. May 15, 2015 SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood. https://mail.google.com/mail/u/0/?tab=wm#inbox/14d587f1089e0791
  2. ↑ 2.0 2.1 FDA Safety Alert. Dec 4, 2015 SGLT2 Inhibitors: Drug Safety Communication - Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. ↑ 4.0 4.1 4.2 Lowes R New FDA Watch List Flags More Drugs Medscape Internal Medicine. July 3, 2017 http://www.medscape.com/viewarticle/882425
  5. ↑ 5.0 5.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
  6. ↑ Zheng SL, Roddick AJ, Aghar-Jaffar R, et al Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes. A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1580-1591. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29677303 https://jamanetwork.com/journals/jama/fullarticle/2678616
  7. ↑ 7.0 7.1 Chang HY, Singh S, Mansour O, Baksh S, Alexander GC Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 2018 Aug 13; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30105373
    Fralick M, Patorno E, Fischer MA Sodium-glucose cotransporter 2 inhibitors and the risk of amputation: Results and challenges from the real world. JAMA Intern Med 2018 Aug 13; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30105365
  8. ↑ 8.0 8.1 FDA Safety Alert. Ag 29, 2018 SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm618908.htm
  9. ↑ 9.0 9.1 9.2 Ueda P, Svanstrom H, Melbye M et al Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:k4365 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30429124 https://www.bmj.com/content/363/bmj.k4365
  10. ↑ Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018 Nov 10; [e-pub]. (https://doi.org/10.1016/S0140-6736(18)32590-X) PMID: https://www.ncbi.nlm.nih.gov/pubmed/30424892
    Verma S, Juni P, Mazer CD. Pump, pipes, and filter: Do SGLT2 inhibitors cover it all? Lancet 2018 Nov 10; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30424891
  11. ↑ Writing Committee, Das SR, Everett BM, Birtcher KK et al 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. Nov 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30497881 <Internet> http://www.onlinejacc.org/content/early/2018/11/23/j.jacc.2018.09.020
  12. ↑ 12.0 12.1 12.2 12.3 Bersoff-Matcha SJ, Chamberlain C, Cao C et al Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019. May 7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31060053 https://annals.org/aim/article-abstract/2732837/fournier-gangrene-associated-sodium-glucose-cotransporter-2-inhibitors-review-spontaneous
  13. ↑ 13.0 13.1 Dave CV, Schneeweiss S, Kim D et al Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019. July 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31357213 https://annals.org/aim/article-abstract/2739786/sodium-glucose-cotransporter-2-inhibitors-risk-severe-urinary-tract-infections
    Filion KB, Yu OH Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence. Ann Intern Med. 2019. July 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31357211 https://annals.org/aim/article-abstract/2739787/sodium-glucose-cotransporter-2-inhibitors-severe-urinary-tract-infections-reassuring
  14. ↑ 14.0 14.1 14.2 Douros A et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study. Ann Intern Med 2020 Jul 28; PMID: https://www.ncbi.nlm.nih.gov/pubmed/32716707 https://www.acpjournals.org/doi/10.7326/M20-0289
  15. ↑ 15.0 15.1 Shi FH, Li H, Yue J et al Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes. A Meta-Analysis of 51 Randomized Clinical Trials. J Clin Endocrinol Metab. 2020;105(11) PMID: https://www.ncbi.nlm.nih.gov/pubmed/32841351 https://www.medscape.com/viewarticle/938944
  16. ↑ 16.0 16.1 Monaco K SGLT-2 Inhibitors Cleared of Bone Fracture Qualms in Older T2D Patients. New Medicare users of three classes of antidiabetic agents were compared. MedPage Today October 27, 2021 https://www.medpagetoday.com/endocrinology/diabetes/95290
    Zhuo M, Hawley CE, Paik JM et al Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34705014 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785536
  17. ↑ 17.0 17.1 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  18. ↑ 18.0 18.1 Schwartz B Fast Five Quiz: Penis Conditions and Disorders Medscape. Nov 29, 2022 https://reference.medscape.com/viewarticle/984322
  19. ↑ 19.0 19.1 D'Andrea E et al. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med 2023 Feb 6; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36745425 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2800884
  20. ↑ 20.0 20.1 Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. 2021 Apr;55(4):543-548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32808541 Review.
  21. ↑ 21.0 21.1 NEJM Knowledge+ Endocrinology
Retrieved from "https://aaushi.info/w/index.php?title=A50453&oldid=1184213"